Overview

Pharmacokinetics of IV Formulation

Status:
Withdrawn

Trial end date:
2017-08-01

Target enrollment:

Participant gender:

Summary

Open label evaluation of a single intravenous dose of F901318 to healthy male and female subjects with pharmacokinetic and safety and tolerability evaluation.

Phase:

Phase 1

Details

Lead Sponsor:

F2G Biotech GmbH
F2G Ltd.

Collaborator:

Quotient Clinical

Treatments:

Olorofim